NICE wants more Sovaldi data

The U.K.'s NICE said it is "minded not to recommend" Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) for chronic HCV infection, but said it needs more information on the product's cost effectiveness before it can make a final recommendation. According to HCV NS5B polymerase inhibitor, is approved in the EU as part of an all-oral therapy for genotypes 2 and 3 infection; and in combination with ribavirin and pegylated interferon to treat HCV genotypes 1, 4, 5 and 6 infections. In April, NHS England approved L18.7 million ($31.3 million) in funding to cover Sovaldi for advanced HCV patients who are at significant risk of death or who require liver transplants (see BioCentury Extra, April 17). ...